CCL5 and HIV infectious disease: It is well known that chemokine receptor agonists, such as the β-chemokines RANTES (CCL5), MIP-1α (CCL3), and MIP-1β (CCL4), inhibit HIV infection of susceptible cells in vitro (18–21).